The quest to harness the immune system for generating highly effective therapeutic antibodies has faced significant challenges, especially against rapidly mutating pathogens such as HIV, malaria, and influenza. Traditional vaccines can stimulate B cells to develop broadly neutralizing antibodies, but this process is often inefficient and varies widely among individuals. Attempts to genetically modify mature B cells have been limited, as the effects are temporary and diminish when the cells die out.
Researchers at The Rockefeller University have proposed a novel solution by targeting hematopoietic stem and progenitor cells (HSPCs), the foundational source of all B lymphocytes. By programming these stem cells with genetic instructions for producing therapeutic antibodies, the team aims to create a more sustainable method for generating potent immune responses. This innovative approach leverages the immune system’s natural ability to amplify useful cells following vaccination, allowing even a small number of edited stem cells to trigger long-lasting immunity.
Innovative Approach to Cell Editing
“The immune system is inherently inefficient, generating a multitude of cells to defend itself,” explained Harald Hartweger, a research assistant professor in Michel Nussenzweig’s Laboratory of Molecular Immunology. The team aimed to capitalize on the immune system’s capability to amplify rare, beneficial cells. Their study, published in a leading scientific journal, highlights the effectiveness of CRISPR-edited HSPCs, which can mature into B cells that express engineered antibodies when stimulated by vaccination.
Once vaccinated, these edited B cells are prompted to proliferate, differentiate into plasma cells, and produce high levels of the inserted antibodies over an extended period. Remarkably, researchers found that as few as 7,000 edited HSPCs could generate sufficient quantities of long-lasting protective antibodies, demonstrating significant potential for medical applications.
Versatility of Edited B Cells
The platform developed by the researchers is not only effective for antibody production; it also shows promise for various therapeutic proteins. Edited B cells have been observed to secrete non-antibody proteins, indicating potential applications in treating genetic disorders. Furthermore, by combining HSPCs with different genetic instructions, the team successfully engineered immune systems capable of producing multiple antibodies simultaneously. This capability could be particularly advantageous in combating rapidly evolving viruses like HIV.
In initial experiments with human HSPCs, the researchers achieved functional human B cells within an immunodeficient mouse model, marking a promising step toward translational applications in humans.
Vision for Future Applications
“We aim to create a permanent genomic change with a single injection, enabling the body to produce therapeutic proteins,” Hartweger stated. These proteins could range from universally protective antibodies against diseases like HIV and influenza to other therapeutic agents for various health conditions.
The research team is now preparing for preclinical trials in non-human primates to assess the efficacy of this approach against HIV. They are also investigating whether similar gene editing techniques could be applied to T cells, potentially broadening the scope of this innovative therapeutic strategy.
Long-Term Goals for Therapy
The overarching vision is to establish a versatile and sustainable platform for long-term protein production, addressing a wide array of medical challenges. Hartweger envisions applications in treating infectious diseases, protein deficiencies, autoimmune conditions, metabolic disorders, and even cancer.
Nussenzweig succinctly summed up the significance of the study: “This research presents a workaround for the antibody challenge, offering a viable long-lasting solution in the absence of a universal HIV vaccine.”
Key Takeaways
- Researchers at The Rockefeller University are pioneering the use of edited hematopoietic stem and progenitor cells to produce therapeutic antibodies.
- A small number of genetically modified stem cells can trigger an extensive immune response following vaccination.
-
The platform is versatile, allowing for the production of both antibodies and other therapeutic proteins.
-
Preliminary results in human models show promise for future applications in treating various diseases.
-
Ongoing efforts are directed at preclinical testing and expanding the approach to T cells for broader therapeutic applications.
The advancement in stem cell gene editing not only holds the potential to revolutionize immunotherapy but may also pave the way for new treatments across various medical fields. This innovative approach may ultimately transform how we combat diseases that have long posed significant challenges to human health.
Read more → www.genengnews.com